Intercell teams up with GSK for patch-based vaccines
This article was originally published in Clinica
Austrian biotech firm Intercell is to collaborate with GlaxoSmithKline (GSK) Biologicals on the development and commercialisation of needle-free, patch-based vaccines. The agreement will see the two firms commercialise Intercell’s vaccine patch for travellers’ diarrhoea (TD), which is currently in phase III trials, and work on future pandemic influenza vaccination patch technology. The companies will combine GSK’s patch technology with Intercell’s candidate vaccines. There are presently no vaccines available for TD, said the company. Financial terms of the deal were not disclosed. According to Vienna-based Intercell, the patch technology could provide a new way of delivering vaccines faster, more easily and with fewer doses. Intercell says that each year, around 20 million travellers develop TD while visiting endemic areas such as Asia, Africa and South America.